JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 4592.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
SanBio Company Limited’s quoted price sits in the lower half of its reported 52-week range, 68.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SanBio Company Limited’s next earnings report is currently expected on Dec 10, 2026, with estimated earnings per share of -¥16. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SanBio Company Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| ¥0 |
| Q3 2025 | Dec 16, 2024 | -¥12+33.21% vs estimate | ¥0 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥6,651+¥180 (+2.78%)
Takeda Pharmaceutical Company Limited’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
¥273-¥5 (-1.8%)
Healios K.K.’s quoted price sits in the lower half of its reported 52-week range, 45.29% below the high.
¥629-¥138 (-17.99%)
Japan Tissue Engineering Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.15% below the high.
¥139-¥7 (-4.79%)
StemRIM’s quoted price sits in the lower half of its reported 52-week range, 62.23% below the high.
¥149-¥5 (-3.25%)
Kidswell Bio Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
¥403-¥16 (-3.82%)
J-Pharma Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.19% below the high.
¥20-¥1 (-4.76%)
MEDINET Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
